Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A new CGM that just was approved for use in Europe, called sugarBEAT, from Nemaura Medical, in the United Kingdom, was designed only after “multiple focus group studies and feedback from clinical studies” were taken into account, according to Bashir Timol, Director of Strategy and Corporate Development at Nemaura. The company put user-experience high on their list of considerations in designing a new piece of tech that might ease the burden of monitoring blood sugar.
The system is expected to hit the market in Europe by the end of the year, according to a news release from Nemaura. The company was spun off its parent company, Nemaura Pharma, which started in 2005 to “develop state-of-the-art transdermal drug-delivery systems for a wide range of drugs and vaccines.” The company says it has filed for FDA approval for an Alzheimer’s drug delivery patch, and is also developing “more than 16 drugs in house.”
The reason the end user experience was so paramount in developing the CGM product, Timol says, is because the user has become a key arbiter in deciding how technology is designed. “Today, CGMs are expected to be more user friendly and discreet, and technology has moved on to enable that to happen, hence our R&D efforts have been guided by trying to enhance the user experience within the technical limits of our product,” he says. “Our decision to move from a ‘watch’ to a ‘wireless patch’ based format was driven by our desire to try easily integrate into the App-centric smart device — phone, watch, tablet —lifestyle many users are adopting.”
https://asweetlife.org/needle-free-patch-cgm-to-launch-in-europe/
I'm also a bit sceptical. 'Drawing glucose out of the skin'? Hmmm...Interesting about the 'MARD', though.
The system is expected to hit the market in Europe by the end of the year, according to a news release from Nemaura. The company was spun off its parent company, Nemaura Pharma, which started in 2005 to “develop state-of-the-art transdermal drug-delivery systems for a wide range of drugs and vaccines.” The company says it has filed for FDA approval for an Alzheimer’s drug delivery patch, and is also developing “more than 16 drugs in house.”
The reason the end user experience was so paramount in developing the CGM product, Timol says, is because the user has become a key arbiter in deciding how technology is designed. “Today, CGMs are expected to be more user friendly and discreet, and technology has moved on to enable that to happen, hence our R&D efforts have been guided by trying to enhance the user experience within the technical limits of our product,” he says. “Our decision to move from a ‘watch’ to a ‘wireless patch’ based format was driven by our desire to try easily integrate into the App-centric smart device — phone, watch, tablet —lifestyle many users are adopting.”
https://asweetlife.org/needle-free-patch-cgm-to-launch-in-europe/
I'm also a bit sceptical. 'Drawing glucose out of the skin'? Hmmm...Interesting about the 'MARD', though.
